POZ Platform Archives

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 447Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 458Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 348Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 420Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 289Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Serina Therapeutics Secures 30 Million Reasons Wall Street Is Warming to Parkinson’s Innovation -( $SER $IBB $XBI )

by John F. Heerdink, Jr. March 18, 2026 868Views 0Likes

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. Parkinson’s Bet…

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

by John F. Heerdink, Jr. June 16, 2025 549Views 0Likes

In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and…

Tag: POZ Platform

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Serina Therapeutics Secures 30 Million Reasons Wall Street Is Warming to Parkinson’s Innovation -( $SER $IBB $XBI )

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

Your Guide To Staying Informed In The Markets